David A. Eberhard

8.2k total citations · 1 hit paper
51 papers, 5.3k citations indexed

About

David A. Eberhard is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David A. Eberhard has authored 51 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 19 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David A. Eberhard's work include HER2/EGFR in Cancer Research (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Cancer Genomics and Diagnostics (9 papers). David A. Eberhard is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Cancer Genomics and Diagnostics (9 papers). David A. Eberhard collaborates with scholars based in United States, Germany and Switzerland. David A. Eberhard's co-authors include Ronald W. Holz, Bruce E. Johnson, Somasekar Seshagiri, Lukas C. Amler, Jeremy Stinson, Thomas Januario, Roy S. Herbst, David H. Johnson, David A. Ramies and Ladislau Steiner and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

David A. Eberhard

51 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 1.2k citations David A. Eberhard, Bruce E. Johnson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Eberhard United States	25	2.5k	2.3k	2.1k	996	492	51	5.3k
Douglas W. Ball United States	41	3.4k 1.4×	2.7k 1.2×	1.1k 0.5×	827 0.8×	307 0.6×	93	7.1k
Oriol Casanovas Spain	32	3.8k 1.6×	2.3k 1.0×	896 0.4×	2.1k 2.1×	440 0.9×	70	6.2k
Francesca Carlomagno Italy	42	2.9k 1.2×	2.4k 1.0×	880 0.4×	688 0.7×	339 0.7×	92	6.2k
Dora Dias‐Santagata United States	44	3.2k 1.3×	3.5k 1.5×	2.2k 1.0×	1.6k 1.6×	327 0.7×	112	7.8k
Karen Cichowski United States	35	3.6k 1.5×	1.5k 0.7×	1.3k 0.6×	840 0.8×	612 1.2×	58	6.6k
Hans Skovgaard Poulsen Denmark	44	2.5k 1.0×	2.0k 0.9×	1.2k 0.6×	1.2k 1.2×	280 0.6×	188	5.9k
Francesco Hofmann Switzerland	30	4.2k 1.7×	1.4k 0.6×	900 0.4×	1.0k 1.0×	424 0.9×	56	5.9k
Massimo Santoro Italy	54	4.4k 1.8×	4.2k 1.9×	1.0k 0.5×	1.1k 1.1×	344 0.7×	114	11.6k
Nina N. Nupponen Finland	35	2.2k 0.9×	999 0.4×	1.4k 0.7×	1.1k 1.1×	165 0.3×	64	4.5k
Arnab Chakravarti United States	45	3.2k 1.3×	1.3k 0.6×	1.1k 0.5×	2.1k 2.1×	391 0.8×	173	6.1k

Countries citing papers authored by David A. Eberhard

Since Specialization

Citations

This map shows the geographic impact of David A. Eberhard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Eberhard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Eberhard more than expected).

Fields of papers citing papers by David A. Eberhard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Eberhard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Eberhard. The network helps show where David A. Eberhard may publish in the future.

Co-authorship network of co-authors of David A. Eberhard

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Eberhard. A scholar is included among the top collaborators of David A. Eberhard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Eberhard. David A. Eberhard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eberhard, David A., C Gillberg, & Eva Billstedt. (2024). Cognitive functioning in adult psychiatric patients with and without attention‐deficit/hyperactivity disorder. Brain and Behavior. 14(7). e3626–e3626. 2 indexed citations

Busch, Evan L., Haitao Chu, David B. Richardson, et al.. (2018). Diagnostic accuracy and prediction increment of markers of epithelial-mesenchymal transition to assess cancer cell detachment from primary tumors. BMC Cancer. 18(1). 82–82. 4 indexed citations

Busch, Evan L., Temitope O. Keku, David B. Richardson, et al.. (2015). Evaluating markers of epithelial-mesenchymal transition to identify cancer patients at risk for metastatic disease. Clinical & Experimental Metastasis. 33(1). 53–62. 19 indexed citations

McShane, Lisa M., Margaret M. Cavenagh, Tracy Lively, et al.. (2013). Criteria for the use of omics-based predictors in clinical trials. Nature. 502(7471). 317–320. 164 indexed citations

McShane, Lisa M., Margaret M. Cavenagh, Tracy Lively, et al.. (2013). Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Medicine. 11(1). 220–220. 85 indexed citations

Potts, Steven J., et al.. (2012). Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Laboratory Investigation. 92(9). 1342–1357. 99 indexed citations

Potts, Steven J., Sarah Huff, David A. Eberhard, et al.. (2012). Tissue Pattern Recognition Error Rates and Tumor Heterogeneity in Gastric Cancer. Applied immunohistochemistry & molecular morphology. 21(1). 21–30. 6 indexed citations

Varella‐Garcia, Marileila, Joachim Diebold, David A. Eberhard, et al.. (2009). EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. Journal of Clinical Pathology. 62(11). 970–977. 96 indexed citations

Herbst, Roy S., Angela M. Davies, Ronald B. Natale, et al.. (2007). Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 13(20). 6175–6181. 79 indexed citations

10.

Gordon, Michael S., Daniela Matei, Carol Aghajanian, et al.. (2006). Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status. Journal of Clinical Oncology. 24(26). 4324–4332. 187 indexed citations

11.

Haas-Kogan, Daphne A., Michael D. Prados, Tarık Tihan, et al.. (2005). Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib. JNCI Journal of the National Cancer Institute. 97(12). 880–887. 368 indexed citations

12.

Zhang, Yan, David A. Eberhard, Gretchen Frantz, et al.. (2004). GEPIS—quantitative gene expression profiling in normal and cancer tissues. Bioinformatics. 20(15). 2390–2398. 22 indexed citations

13.

Jin, Hongkui, Renhui Yang, Wei Li, et al.. (2003). Early Treatment with Hepatocyte Growth Factor Improves Cardiac Function in Experimental Heart Failure Induced by Myocardial Infarction. Journal of Pharmacology and Experimental Therapeutics. 304(2). 654–660. 27 indexed citations

14.

Eberhard, David A., et al.. (1997). Histopathology of arteriovenous malformations after gamma knife radiosurgery. Journal of neurosurgery. 87(3). 352–357. 244 indexed citations

15.

Fountain, Nathan B. & David A. Eberhard. (1996). Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Neurology. 46(1). 190–197. 82 indexed citations

16.

Eberhard, David A., et al.. (1995). 1027 Pathologic effects of gamma-knife radiosurgery on arteriovenous malformations. International Journal of Radiation Oncology*Biology*Physics. 32. 236–236. 2 indexed citations

17.

Eberhard, David A.. (1994). Two-year-old Boy with Proteus Syndrome and Fatal Pulmonary Thromboembolism. Pediatric Pathology. 14(5). 771–779. 22 indexed citations

18.

Vogl, Thomas J., et al.. (1992). Die Anwendung der „Cine-Technik” in der MRT-Diagnostik des Kiefergelenkes. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 156(3). 232–237. 3 indexed citations

19.

Eberhard, David A. & Ronald W. Holz. (1991). Calcium promotes the accumulation of polyphosphoinositides in intact and permeabilized bovine adrenal chromaffin cells. Cellular and Molecular Neurobiology. 11(3). 357–370. 17 indexed citations

20.

Eberhard, David A. & Ronald W. Holz. (1987). Cholinergic Stimulation of Inositol Phosphate Formation in Bovine Adrenal Chromaffin Cells: Distinct Nicotinic and Muscarinic Mechanisms. Journal of Neurochemistry. 49(5). 1634–1643. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact